Sirius Therapeutics Secures Nearly $50 Million in Series B2 Financing to Advance Clinical Development of siRNA Therapies for Cardiovascular and Metabolic Diseases

Today (May 9), it was announced that Sirius Therapeutics successfully completed a nearly 50 million USD B2 round of financing to accelerate its...Novel Small Interfering RNA (siRNA) Therapies for Cardiovascular Metabolic Diseasesclinical development and continue to innovate its next-generation RNA delivery technology. This round of financing was led by a globally renowned industry investment institution, with participation from BioTrack Capital, existing investors OrbiMed, Creacion Ventures, and Shanghai Hankang Private Equity Fund Management Co., Ltd.

Dr. Qunsheng Ji, CEO of Sirius Therapeutics, stated: "The successful completion of this round of financing is a full recognition by both new and existing investors of the progress we have made to date and our future strategy. We sincerely thank all our investors. The proceeds from this financing will be used to further advance our clinical pipeline and enrich our product portfolio, with the aim of accelerating the development of disruptive siRNA therapies for chronic disease prevention and treatment, benefiting patients worldwide."

Dr. Ji added that the company currently has three clinical-stage projects and multiple preclinical product pipelines. Among them, the most advancedSRSD107, a New Anticoagulant Therapy, Represents a New Generation of Long-Acting Anticoagulants for the Treatment and Prevention of Thromboembolic Diseases, has submitted a Phase 2 clinical trial application in Europe to the European Medicines Agency (EMA).Novel siRNA Therapy SRSD216 Targeting High Lipoprotein(a)It has been approved by the U.S. FDA and China NMPA, and is currently conducting Phase 1 clinical trials. AnothersiRNA Therapy for HyperlipidemiaSRSD101 is also advancing clinical development in an orderly manner in China.

Sirius Therapeutics is an innovative biotechnology company dedicated to advancing human health and well-being by developing groundbreaking siRNA therapies for the prevention and treatment of chronic diseases. Founded in 2021, Sirius Therapeutics was incubated by an international management team and globally renowned healthcare investment institutions. The company adopts an international strategic positioning, leveraging talent and resources from both the U.S. and China in the field of small nucleic acid therapeutics. It has established a research and innovation discovery hub in the U.S., along with a global translational medicine center in China. Utilizing its core technology platform for small nucleic acid drug development, the company has advanced multiple "first-in-class" or...A differentiated product pipeline with "best-in-class" potential. The company has cumulatively raised nearly 150 million US dollars in financing.

References:

[1]Sirius Therapeutics Press Release